Most private insurance plans do not cover IV ketamine infusions. Ketamine delivered intravenously remains an off-label use, and major insurers like Aetna explicitly classify it as “experimental, investigational, or unproven” for depression, suicidal ideation, and chronic pain. However, a related nasal spray called Spravato (esketamine) does have FDA approval and is more likely to be covered, and the VA health system has a formal protocol for IV ketamine in specific cases. The path to any reimbursement depends heavily on what type of ketamine treatment you’re pursuing, what condition it’s for, and who your insurer is.
Why Most Insurers Deny IV Ketamine Claims
The core issue is FDA approval. Ketamine is FDA-approved as an anesthetic, not as a treatment for depression, PTSD, or chronic pain. When doctors administer it by IV for these conditions, they’re using it “off-label.” Insurers generally won’t cover off-label uses unless strong clinical guidelines or compendium listings support them, and ketamine for mental health hasn’t crossed that threshold with most private payers.
Aetna’s published policy is representative of the industry: the company considers ketamine via any route (IV, intramuscular, oral, intranasal, or under-the-skin injection) unproven for depression, suicidal ideation, and other psychiatric or pain conditions. Most other large commercial insurers, including UnitedHealthcare and many Blue Cross Blue Shield plans, take similar positions. Even ketamine-assisted psychotherapy, where infusions are paired with talk therapy, is classified the same way.
Spravato (Esketamine) Has a Different Status
Spravato is a nasal spray form of esketamine, a close chemical relative of ketamine. It received FDA approval for treatment-resistant depression in 2019 and has since been approved for depressive symptoms in adults with major depression accompanied by suicidal thoughts. In January 2025, the FDA expanded approval to allow Spravato as a standalone treatment for treatment-resistant depression, without requiring a companion oral antidepressant.
Because Spravato has FDA approval, it falls into a different insurance category. Medicare has billing codes specifically for its administration, and many private insurers cover it, though typically with prior authorization requirements. Anthem, for example, reviews Spravato requests using standardized clinical criteria and requires providers to get authorization before starting treatment. The practical experience for patients is that Spravato is more accessible through insurance, but you’ll likely need documentation showing you’ve tried and failed other antidepressants first.
One important distinction: Spravato must be administered in a certified healthcare setting under observation. You cannot pick it up at a pharmacy and use it at home. Each session involves about two hours at a clinic, which is part of what insurers are paying for.
What the VA Covers for Veterans
The VA health system is one of the few places where IV ketamine infusions are available through a formal, covered protocol. The VA’s national guidance provides access to IV ketamine for treatment-resistant major depression and severe suicidal ideation, but the eligibility criteria are strict.
To qualify, a veteran must meet one of two conditions: either they haven’t achieved remission after two antidepressant trials (including at least one augmentation strategy) in their current depressive episode, plus four total adequate antidepressant trials over their lifetime, or they’re hospitalized with treatment-resistant depression and active suicidal thoughts or behavior. On top of that, the veteran needs to show moderate to severe depressive symptoms on a standardized screening tool within the past 30 days.
The VA also maintains a lengthy list of disqualifying conditions, including a history of psychotic disorders, bipolar disorder, dementia, uncontrolled high blood pressure, active substance use disorders (other than tobacco), and prior nonresponse to ketamine or esketamine. Veterans who receive maintenance infusions undergo regular reassessment to confirm ongoing need.
What You’ll Pay Out of Pocket
Without insurance coverage, ketamine infusions are entirely self-pay for most people. An initial consultation with evaluation and treatment planning runs $250 to $500. Individual infusion sessions cost between $400 and $800 each.
The standard starting protocol is six infusions spread over two to three weeks, putting the initial phase at $2,400 to $4,800. After that, many patients need periodic maintenance infusions to sustain the benefits, each costing the same $400 to $800. Over a year of monthly maintenance, that adds another $4,800 to $9,600. These costs add up quickly, which is why the insurance question matters so much to people considering this treatment.
Submitting a Superbill for Partial Reimbursement
Some patients have had limited success getting reimbursed through out-of-network benefits by submitting a superbill, which is an itemized receipt your clinic provides that you then file with your insurer. The results are inconsistent and often disappointing.
The pattern that emerges from patients who’ve tried this route: insurers may reimburse for the provider consultation fee and possibly the IV insertion, but not for the ketamine medication itself or the infusion monitoring time, which is where most of the cost sits. Some clinics intentionally code the superbill to emphasize the observation and monitoring components rather than the drug, since the medication cost is minimal (ketamine itself costs very little) and the clinical monitoring is the expensive part.
Several factors influence whether you’ll get anything back. If your plan has out-of-network benefits, reimbursed amounts typically apply toward your out-of-network deductible rather than being paid directly to you. Many people find their out-of-network deductible is so high that even monthly sessions won’t reach it within a calendar year. One important detail: some plans require that a personal physician referred you or prescribed the treatment. If you self-referred to a ketamine clinic, your plan may reject the claim entirely.
If you want to try this route, ask the ketamine clinic upfront whether they provide superbills and what billing codes they use. Call your insurer before your first session to ask specifically about out-of-network mental health benefits, your deductible, and whether off-label infusion services are subject to any exclusions.
How to Improve Your Chances of Coverage
Your best leverage for any insurance coverage comes from building a documented treatment history. Insurers and coverage protocols consistently require evidence that you’ve tried and failed conventional treatments first. For depression, that means trials of multiple antidepressants at adequate doses for adequate durations, ideally including at least one augmentation strategy (where a second medication is added to boost the first).
If your goal is to eventually access covered treatment, the most reliable path is asking your psychiatrist about Spravato rather than IV ketamine. Because Spravato has FDA approval and established billing codes, it fits within the standard prior authorization framework that insurers already use. Your provider submits documentation of your diagnosis, your treatment history, and your current symptom severity. The insurer reviews it against their clinical criteria and approves or denies.
For veterans enrolled in VA healthcare, the path is more straightforward: work with your VA mental health provider to document your treatment history and symptom severity, and ask whether you meet the criteria for the VA’s ketamine infusion protocol. The VA system handles this internally rather than through a traditional insurance claims process.
For everyone else paying out of pocket for IV ketamine, it’s worth asking clinics about payment plans, sliding scale fees, or package pricing for the initial six-infusion series. Some clinics offer modest discounts when you prepay for the full induction course.